Reading NMRA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track NMRA free→Reading NMRA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track NMRA free→NASDAQHealth CareBiotechnologySnapshot 2026-06-16
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is neutral. Earnings quality is fragile, meaning profits lack cash support. Management's recent track record has been steady, but it is capital unfriendly. Risk is elevated, and the sector backdrop is a headwind. The market is in a Mania phase. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 0 valuation methods, at three horizons. Current price $1.56. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Not enough valuation methods to set a 12-month read yet.
Not enough peers to compare yet.
Self-history needs ~20 months of data.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
Over the trailing year it converted -0.77x of net income into operating cash flow. Historically, Health Care names rated fragile grew net income 40% of the time over the next year (vs 56% for the rest of the cohort, n=1703).
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity.
3 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 56% of the time over the next year (vs 52% for the rest of the cohort, n=618).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.25 → $-0.24 (+4.1% / 30d). 3 raised, 1 cut, 9 covering analysts.
0 upgrades, 0 downgrades / 30d. 78% of analysts rate Buy.
1 positive, 3 negative / 30d. See F4 management tile for the event list.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$232.
How much price usually moves either way.
On a bad day, this stock has moved -$736.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $7,453.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
No named catalysts to watch right now. Check back after the next earnings report.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for NMRA yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Entry into a Material Definitive Agreement. On June 10, 2026, Neumora Therapeutics, Inc. (the “Company” or “Neumora”) as borrower, entered into a Third Amendment to the Loan and Security Agreement (the “Third Amendment”), with K2 HealthVentures LLC as a lender, and the lenders party thereto from time to time (collectively, “Lenders”, and each, a “Lender”), and K2 HealthVentures LLC, as administrative agent for Lenders. The Third Amendment modified the Company’s existing Loan Agreement and Sec…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
No score history yet for this stock.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Biotechnology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
NMRA Neumora Therapeutics Inc | — | — | elevated |
ABBV AbbVie | Above typical Show detailsSector percentile: 85 of 100 | fair | low |
AMGN Amgen | Above typical Show detailsSector percentile: 81 of 100 | full | moderate |
GILD Gilead Sciences | Above typical Show detailsSector percentile: 99 of 100 | fair | moderate |
VRTX Vertex Pharmaceuticals | Above typical Show detailsSector percentile: 80 of 100 | expensive | moderate |
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Ensure sufficient cash and cash equivalents to support operations into the third quarter of 2027.
Stated in 5 of last 5 quarters. The company expects its cash and cash equivalents as of March 31, 2026, will enable it to fund its operating plan into the third quarter of 2027. Despite recurring statements, the financials show persistent negative cash from operations, indicating limited progress in achieving this priority.
“The Company expects its cash and cash equivalents as of March 31, 2026, will enable it to fund its operating plan into the third quarter of 2027.”
“The Company expects that its cash, cash equivalents and marketable securities as of December 31, 2025, will enable it to fund its operating plan into the third quarter of 2027.”
“Cash, cash equivalents and marketable securities expected to support operations into the third quarter of 2027.”
“The Company expects that its cash, cash equivalents and marketable securities as of September 30, 2025, will enable it to fund its operating plan into 2027.”
Finish the multiple ascending dose cohort study for NMRA-511 by the fourth quarter of 2026.
Stated in 2 of last 2 quarters. The company plans to complete the NMRA-511 dose study by Q4 2026. However, there is no specific financial data or milestone achievement reported this quarter to indicate progress toward this goal, suggesting limited substantive delivery so far.
“Complete multiple ascending dose cohort evaluating higher doses in healthy elderly volunteers in the fourth quarter of 2026.”
“The Company plans to complete the NMRA-511 dose study by the fourth quarter of 2026.”
Start the Phase 2b dose-ranging study for NMRA-511 by the end of 2026.
Stated in 2 of last 2 quarters. The company plans to initiate the NMRA-511 Phase 2b study by the end of 2026. No specific financial or operational milestones have been reported this quarter to demonstrate progress, indicating a recurring focus with narrow delivery so far.
“Data from this study will inform dose selection for a Phase 2b dose ranging study that the Company plans to initiate by the end of 2026.”
“The Company plans to initiate the NMRA-511 Phase 2b study by the end of 2026.”
above, the Company expects its current cash and cash equivalents to provide runway into the third quarter of 2027. KOASTAL Summary Results The KOASTAL-2 and -3 studies enrolled 430 and 422 adult patients with MDD, respectively. The primary endpoint of both KOASTAL-2 and -3 was change from baseline (“CFB”) to week 6 on the Montgomery-Åsberg Depression Rating Scale (MADRS). In the KOASTAL-2 study patients treated with navacaprant 80 mg (n = 217) demonstrated a similar CFB to those treated with…
Creation of a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement of a Registrant. The description set forth under
Other Events. Pipeline and Business Update The Company is focused on the following near-term anticipated potential milestones: • NMRA-511 (V1a receptor antagonist, Alzheimer’s disease agitation): • Complete multiple ascending dose cohort evaluating higher doses in healthy elderly volunteers in the fourth quarter of 2026. • Data from this study will inform dose selection for a Phase 2b dose ranging study that the Company plans to initiate by the end of 2026. • NMRA-898 (M4 positive allosteric…
of this Current Report on Form 8-K, including the attached Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific…